Anxiety Disorders or Depressive Disorders with anxiety, affect about 3/5 pregnancies. It is known that if left untreated, these disorders are associated with poor delivery outcomes, ongoing mental illness, and negative effects on the child. The COVID-19 pandemic has created heightened anxiety in many people especially the most vulnerable. As a result, the investigators have seen that pregnant women report even higher rates of anxiety than in the past. Talk therapy is recommended but is underused in part because it takes a long time to learn and use. The COVID crisis has added another layer of complexity in that in-person treatment is not routinely available. The investigator team has adapted a talk therapy treatment, "Mindful adaptive practice in pregnancy (MAPP)" where women are taught skills to reduce anxiety. This treatment is done virtually over the internet in a synchronous group format. The overall objective of this study is to assess the feasibility, acceptability, and adherence to the clinical trial protocol evaluating MAPP on anxiety symptoms among pregnant women. This synchronous virtual treatment is novel and has the potential to change clinical practice as it will effectively reduce anxiety, takes a short time to learn and women will have access to it regardless of living in rural or remote areas. The results of this study will guide the development of a larger multi-site randomized controlled trial (RCT).
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
The number of participants screened positive for anxiety by the GAD-7 who are eligible for the study.
Timeframe: 11 months
The rate of recruitment as assessed by the number of participants recruited
Timeframe: 11 months
Reasons for non-participation as recorded by participants
Timeframe: 11 months
Participant acceptability of treatment as measured by the Treatment Acceptability Scale
Timeframe: 6 weeks
Participant acceptability of treatment as measured by the Acceptability of Internet Delivery (AID)/ Experiences of Therapy Questionnaire
Timeframe: 6 weeks
Therapist acceptability of treatment as measured by the Acceptability of Intervention Measures
Timeframe: 6 weeks
Therapist acceptability of treatment as measured by questions on the Intervention Appropriateness Measure (IAM)
Timeframe: 6 weeks
Therapist acceptability of treatment as measured by the Feasibility of Intervention Measure (FIM) Questionnaire
Timeframe: 6 weeks
Participant Adherence to therapy as measured by proportion of participants who attend each session of therapy
Timeframe: 4 weeks
Participant Adherence to therapy as measured by proportion of participants who attend all sessions of therapy
Timeframe: 4 weeks
Participant Adherence to therapy as measured by the number completing follow-up questionnaires at 6, 12, and 24 weeks
Timeframe: After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Participant Adherence to therapy as measured by recorded reasons for dropout
Timeframe: After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy
Therapist Adherence to Therapy as assessed by therapist adherence checklists
Timeframe: After therapy (4 weeks), 3 months post-therapy, and 6 months post-therapy